JERUSALEM (Reuters) – Israeli medical software company DreaMed Diabetes said on Monday it was partnering with Yale New Haven Health System to use artificial intelligence (AI) in monitoring insulin and glucose levels in children with Type 1 diabetes.
Read more here.
